Related Experiment Video
Updated: Sep 3, 2025

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Percutaneous transeptal mitral valve endocarditis debulking with AngioVac aspiration system
Sehrish Memon1, Scott Goldman2, Katie M Hawthorne1
1Division of Cardiovascular and Structural Heart Disease, Lankenau Medical Center and Lankenau Institute of Medical Research, Wynnewood, Pennsylvania, USA.
Percutaneous transseptal debulking using the AngioVac system offers a novel approach for treating mitral valve endocarditis in high-risk patients. This technique shows promise for inoperable patients, potentially reducing morbidity and mortality.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Medical Device Technology
Background:
- Left-sided infective endocarditis (IE), particularly mitral valve endocarditis (MVE), poses significant risks in patients deemed inoperable or high surgical risk.
- High surgical mortality in the acute phase of IE often precludes valve surgery, leaving patients vulnerable to severe sequelae like stroke and sepsis.
Observation:
- This case report details the percutaneous transseptal debulking of mitral valve vegetation using the AngioVac system in an inoperable patient with methicillin-sensitive Staphylococcus aureus MVE.
- The procedure involved meticulous preprocedural planning, including optimal transseptal puncture, use of a cerebral protection device, and venous extracorporeal membrane oxygenation (ECMO) for reinfusion to mitigate complications.
Findings:
- The AngioVac system, typically used for right-sided cardiac issues, was adapted for left-sided MVE in a challenging patient population.
- Key procedural considerations included minimizing embolic events and avoiding large arterial access complications.
Implications:
- Percutaneous debulking with AngioVac presents a potential alternative to surgery for inoperable patients with left-sided IE.
- Further randomized studies are essential to validate these techniques and establish the efficacy of AngioVac for left-sided IE in high-risk cohorts.
Related Concept Videos
Endocarditis III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Endocarditis IV: Nursing Management
Endocarditis I: Introduction
Mitral Valve Prolapse II: Assessment and Management

